American Society of Hematology

Figure 3

$Figure 3. Erythroid lineage–restricted Jak2V617F expression results in an attenuated MPN phenotype. (A) Jak2 allele-specific PCR performed on Jak2+/+ E2Acre+, Jak2+/VFE2Acre+, and Jak2+/VFEpoRCre+ LSK, MEP, or GMP cells purified from primary mice. Jak2WT and Jak2V617F refer to forward primers (a common reverse primer was used). NTC indicates no template control. Results demonstrate absent Jak2V617F expression in Jak2+/+ cells, Jak2V617F expression in all Jak2+/VFE2Acre+ cell populations and Jak2V617F expression in Jak2+/VFEpoRCre+ MEP cells only. (B) WBC count, hematocrit, and platelet counts of age-matched Jak2+/+E2Acre+, Jak2+/+EpoRcre+, Jak2+/VFEpoRcre+, and Jak2+/VFE2Acre+ mice aged 8-12 weeks (mean ± SEM; n = 4 in each group);*P < .05, **P < .0005. (C) Frequency of CD71+, Ter119+ erythroid precursors in spleen from age-matched Jak2+/+E2Acre+, Jak2+/+EpoRcre+, Jak2+/VFEpoRcre+, and Jak2+/VFE2Acre+ mice (mean ± SEM; n = 4 in each group); **P < .0005. (D) Serum EPO levels from age-matched Jak2+/+E2Acre+, Jak2+/VFEpoRcre+, and Jak2+/VFE2Acre+ mice (mean ± SEM; n = 8 in each group); **P < .001. (E) Frequency of LSK and LK cells in BM from age-matched Jak2+/+E2Acre+, Jak2+/+EpoRcre+, Jak2+/VFEpoRcre+, and Jak2+/VFE2Acre+ mice (mean ± SEM; n = 4 in each group); *P < .05. (F) Frequency of CMP, GMP, and MEP cells in BM from age-matched Jak2+/+E2Acre+, Jak2+/+EpoRcre+, Jak2+/VFEpoRcre+, and Jak2+/VFE2Acre+ mice (mean ± SEM; n = 4 in each group); *P < .05. (G) The percentage of donor chimerism assessed in peripheral blood of recipients of Jak2+/VFE2Acre+ or Jak2+/VFEpoRcre+ unfractionated BM (mean ± SEM, n = 4 in each group). (H) Hematocrit of recipients of Jak2+/VFE2Acre+ or Jak2+/VFEpoRcre+ unfractionated BM (mean ± SEM, n = 4 in each group).$

Erythroid lineage–restricted Jak2V617F expression results in an attenuated MPN phenotype. (A) Jak2 allele-specific PCR performed on Jak2^+/+ E2Acre⁺, Jak2^+/VFE2Acre⁺, and Jak2^+/VFEpoRCre⁺ LSK, MEP, or GMP cells purified from primary mice. Jak2WT and Jak2V617F refer to forward primers (a common reverse primer was used). NTC indicates no template control. Results demonstrate absent Jak2V617F expression in Jak2^+/+ cells, Jak2V617F expression in all Jak2^+/VFE2Acre⁺ cell populations and Jak2V617F expression in Jak2^+/VFEpoRCre⁺ MEP cells only. (B) WBC count, hematocrit, and platelet counts of age-matched Jak2^+/+E2Acre⁺, Jak2^+/+EpoRcre⁺, Jak2^+/VFEpoRcre⁺, and Jak2^+/VFE2Acre⁺ mice aged 8-12 weeks (mean ± SEM; n = 4 in each group);*P < .05, **P < .0005. (C) Frequency of CD71⁺, Ter119⁺ erythroid precursors in spleen from age-matched Jak2^+/+E2Acre⁺, Jak2^+/+EpoRcre⁺, Jak2^+/VFEpoRcre⁺, and Jak2^+/VFE2Acre⁺ mice (mean ± SEM; n = 4 in each group); **P < .0005. (D) Serum EPO levels from age-matched Jak2^+/+E2Acre⁺, Jak2^+/VFEpoRcre⁺, and Jak2^+/VFE2Acre⁺ mice (mean ± SEM; n = 8 in each group); **P < .001. (E) Frequency of LSK and LK cells in BM from age-matched Jak2^+/+E2Acre⁺, Jak2^+/+EpoRcre⁺, Jak2^+/VFEpoRcre⁺, and Jak2^+/VFE2Acre⁺ mice (mean ± SEM; n = 4 in each group); *P < .05. (F) Frequency of CMP, GMP, and MEP cells in BM from age-matched Jak2^+/+E2Acre⁺, Jak2^+/+EpoRcre⁺, Jak2^+/VFEpoRcre⁺, and Jak2^+/VFE2Acre⁺ mice (mean ± SEM; n = 4 in each group); *P < .05. (G) The percentage of donor chimerism assessed in peripheral blood of recipients of Jak2^+/VFE2Acre⁺ or Jak2^+/VFEpoRcre⁺ unfractionated BM (mean ± SEM, n = 4 in each group). (H) Hematocrit of recipients of Jak2^+/VFE2Acre⁺ or Jak2^+/VFEpoRcre⁺ unfractionated BM (mean ± SEM, n = 4 in each group).

This Feature Is Available To Subscribers Only